Structure Therapeutics Inc. American Depositary Shares Asset Resilience Ratio
Structure Therapeutics Inc. American Depositary Shares asset resilience ratio. Structure Therapeutics Inc. American Depositary Shares (GPCR) has an Asset Resilience Ratio of 75.07% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GPCR defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Structure Therapeutics Inc. American Depositary Shares (2020–2025)
Asset resilience ratio of Structure Therapeutics Inc. American Depositary Shares from 2020 to 2025. This chart shows how Structure Therapeutics Inc. American Depositary Shares's Asset Resilience Ratio has changed over time. Read GPCR liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Structure Therapeutics Inc. American Depositary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see GPCR total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.07 Billion | 75.07% |
| Total Liquid Assets | $1.07 Billion | 75.07% |
Asset Resilience Insights
- Very High Liquidity: Structure Therapeutics Inc. American Depositary Shares maintains exceptional liquid asset reserves at 75.07% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Structure Therapeutics Inc. American Depositary Shares Industry Peers by Asset Resilience Ratio
Compare Structure Therapeutics Inc. American Depositary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Structure Therapeutics Inc. American Depositary Shares Asset Resilience Ratio by Year (2020–2025)
Structure Therapeutics Inc. American Depositary Shares asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Structure Therapeutics Inc. American Depositary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 40.82% | $646.57 Million | $1.58 Billion | -38.22pp |
| 2024-12-31 | 79.04% | $714.01 Million | $903.33 Million | +9.02pp |
| 2023-12-31 | 70.02% | $337.53 Million | $482.02 Million | +3.85pp |
| 2022-12-31 | 66.18% | $64.75 Million | $97.84 Million | +64.38pp |
| 2021-12-31 | 1.80% | $2.00 Million | $111.16 Million | -52.70pp |
| 2020-12-31 | 54.50% | $21.09 Million | $38.70 Million | -- |
About Structure Therapeutics Inc. American Depositary Shares
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment… Read more